The company said total net sales for Q3 2024 were $3,738.0 million, down (5)% from $3,933.9 million a year earlier, and U.S. GAAP net earnings were $94.8 million, down (71)%.

1. 01

   The company said total net sales for Q3 2024 were $3,738.0 million, down (5)% from $3,933.9 million a year earlier, and U.S. GAAP net earnings were $94.8 million, down (71)%.

2. 02

   The company said total net sales for Q3 rose 3% on a divestiture-adjusted operational basis, and that new product revenues of about $133 million were driven mainly by Breyna™ and lisdexamfetamine.

3. 03

   Viatris said U.S. GAAP net cash provided by operating activities for Q3 was $827 million, and free cash flow excluding transaction costs primarily related to the divestitures was $866 million. It also said it repaid about $1.9 billion of debt in October, including the make-whole call.

4. 04

   The company said it entered into an exclusive sotagliflozin licensing agreement with Lexicon Pharmaceuticals for markets outside the U.S. and Europe in October. As of November 7, 2024, its adjusted EBITDA outlook was $4,575 to $4,845 million, which included acquired IPR&D of ($25) million, compared with $4,600 to $4,870 million as of August 8.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.